

Predictiv AI – Using Artificial Intelligence to Solve “Real World” Problems

written by InvestorNews | April 15, 2021

Predictiv AI's ThermalPass Part of a Back-to-Work Strategy

The U.S. Centers for Disease Control and Prevention (CDC) reported on Wednesday that approximately 123.9 million people in the U.S. have received at least one dose of a COVID-19 vaccine, representing about 37.3% of the total population.

While vaccination rates are increasing and new COVID-19 cases begin to decline, corporations are developing return-to-the-office strategies that address employees' safety expectations that include regular health and temperature checks.

Temperature Checks Part of the New Workplace Health & Safety Protocols

In order to avoid admitting employees with symptoms, buildings are employing screening measures including restricting entry to a single access point to facilitate temperature checks.

To reduce lineups and wait times, buildings are implementing fast methods of [fever detection](#), and ThermalPass by [Predictiv AI Inc.](#) (TSXV: PAI) is one solution.

ThermalPass Fever Detection System

Last year, Predictiv AI [launched ThermalPass](#), a fever-detection system that instantly screens for higher than normal body

temperatures that could be caused by a virus, such as COVID-19, in order to reduce the risk of spreading the contagion.

The ThermalPass stand-alone unit enhances public safety by providing fast, touch-free scanning of people at entranceways of high-traffic, public locations, and its waterproof design allows for both indoor and outdoor uses.

By integrating 24 medical-grade, non-invasive thermal sensors onto a metal frame, and taking 1200 readings per second, each unit can process one person per second and is perfect for mass screening applications at high-traffic locations such as airports, hospitals, office buildings, and sports stadiums.

Growing Sales and Resellers

This week, Predictiv AI reported that it [signed F2 Factor](#) to provide strategic support services to increase sales and distribution of ThermalPass.

This announcement follows a slew of partnerships signed earlier this year with other resellers including TFG Concepts (TFG), MCL Sustainable Cleaning Solutions (MCL), and Security Identification Systems Corp. (SISCO).

- [TFG](#) is a sales agency with more than 30 years of experience representing manufactures and brands and has partnered before with companies such as Canadian Tire, Costco, Home Depot, and Lowes.
- [MCL](#) plans to focus on the Education, Food Service, and Government sectors across Canada and has almost four decades of experience as a master distributor and their customers include Air Canada, the City of Toronto, and Sunnybrook Hospital.
- [SISCO](#) will integrate ThermalPass with its Fast-Pass® Visitor Management System to help with track-and-trace

efforts for building occupants and visitors.

Last week, Predictiv AI [announced](#) that it has installed multiple ThermalPass temperature scanning devices in Memorial Healthcare System hospital facilities in Broward County, Florida.

Memorial Healthcare is a provider of healthcare services in south Florida through a six-hospital network and various ancillary facilities. By integrating ThermalPass, it has helped eliminate forehead temperature checks and captures core employees' temperature in a more efficient manner.

Dawn de la Vega, Director of Nursing at Memorial Regional Hospital, stated, "With COVID-19 still threatening our community, it's important for us to continue using technology in a way that will help us maximize our team's time and provide quality and safe care to our community."

Predictiv AI's ThermalPass Adopted by Memorial Healthcare System



[Source:](#)

Predictiv AI – Using Artificial Intelligence to Solve “Real World” Problems

Predictiv AI is not a 1-product company but an innovator and strategic operator of emerging technology companies with a focus on artificial intelligence (AI), blockchain solutions, and the Internet-of-Things. The Company's R&D division, AI Labs Inc. (AI Labs), develops new products that solve real-world problems.

In March, Predictiv AI [announced](#) that it partnered with the Waterloo Artificial Intelligence Institute (Waterloo.AI) at the University of Waterloo to allow AI Labs to pursue its AI reach and commercialization efforts and leverage Waterloo.AI as an

extension of the Predictiv AI team.

Harold Godwin, Managing Director of Waterloo.AI, stated, “We are thrilled to have Predictiv AI join as a partner with Waterloo, this is a very exciting time for our university and Waterloo.AI, and we are grateful for the interest and ongoing support of our partners, including our newest, Predictiv AI.”

The collaboration will allow AI Labs to access the artificial intelligence resources at Waterloo.AI, increasing the bandwidth in ideation, research, and development of solutions for real-world problems.

Final Thoughts

Predictiv AI helps businesses and organizations make smarter decisions using AI, deep machine learning, and data science.

As AI continues to be a disruptive technology, investors are looking for ways to profit from it and Predictiv AI could be an avenue for an AI investment.

With a market capitalization of less than C\$11 million, there is still plenty of upside to this Canadian high-tech company.

**Punching above their weight,
Predictmedix keeps nailing the
heavyweight health tech**

partnerships

written by InvestorNews | April 15, 2021

As the world shifts to a “new” normal, employee and customer screenings will be commonplace and [Predictmedix Inc. \(CSE: PMED | OTCQB: PMEDF\)](#) and its solutions are leading the way.

The recent announcement by Predictmedix, regarding the partnership with McGill University, is another example of the relationships that Dr. Rahul Kushwah, COO of Predictmedix, is developing with major corporations and leading healthcare providers as it rolls out Artificial Intelligence (“AI”) health tech solutions.

Predictmedix aims to improve the healthcare system through innovative and cutting-edge digital health technologies. Currently, Predictmedix AI solutions focus on infectious-disease screenings, impairment detection, and remote patient monitoring.

The Company’s products use facial, thermal, video, and audio recognition technologies to determine when individuals are impaired, suffering from an infectious disease, or mental illness. One solution focuses on mass and rapid AI-based screening for COVID-19 symptoms.

Partnerships, Pilots, Trials and Installs – Where Does Predictmedix Find the Time

Earlier this month, Predictmedix announced partnering with a research group led by Dr. Samira Rahimi from McGill University’s Department of Family Medicine.

Dr. Rahimi’s research group will be working with Predictmedix and its three industry verticals: (1) screening for infectious disease associated symptoms; (2) screening for alcohol or cannabis impairment; and, (3) mental health screening.

Dr. Rahul Kushwah commented, “We are extremely excited with the partnership with Dr. Samira Rahimi’s team. Dr. Rahimi is one of the most recognized AI – healthcare scientists in Canada and we look forward to with her and her research team for our 3 major verticals.”

The announcement with McGill is just the latest in a series of pilot projects, partnerships, and product rollouts that Predictmedix has successfully executed this year. Predictmedix believes that it is well-positioned for growth and to capture the current sales momentum into Q1/2021.

Recently, the Company announced that it will be deploying its COVID-19 screening technology along with alcohol and impairment screening technology at [Indian Oil Corporation Ltd \(NSE:IOC.NS\)](#), a multi-billion dollar India-based oil company, and the deployment of its mass screening technology for COVID-19 with [Max Healthcare](#), one of the largest healthcare groups in South Asia, encompassing 14 hospitals with over 3000 doctors.

Predictmedix also announced a collaboration with India-tech giant [Tech Mahindra Ltd \(NSE: TECHM\)](#), to incorporate Predictmedix’s impairment detection technology and COVID-19 solutions into Tech Mahindra’s suite of technologies offered for workplace health and safety across the globe.

Closer to home, the Company, in conjunction with its partner [Juiceworks Exhibits](#), successfully deployed its infectious disease screening technology at [Flow Water](#) in Aurora, Ontario, and a 24-hour pharmacy in Montreal, Quebec.

Used by employees on a daily basis, Predictmedix’s gateway screens individuals, in a non-invasive way, as they walk through and it triggers an alarm if symptoms associated with an infectious disease are detected, such as COVID-19, or signs of impairment due to alcohol or cannabis use.

The screening product consists of hardware, software, multi-spectral cameras, and specialized sensors that are assembled into a gateway, much like a metal detector in an airport, and communicates with Predictmedix's AI model in the cloud.

Remote Patient Monitoring & Telehealth Enterprise Platform with Mobile Wellbeing Acquisition

In June, Predictmedix acquired Mobile Wellbeing, a remote patient monitoring platform, which is strategic for the Company in creating an enterprise platform and allows Predictmedix to enter the telehealth and clinical trials markets.

According to a recent by study Adroit Market Research, the Remote Patient Monitoring Market is anticipated to reach US\$1.9 billion by 2026, growing at a CAGR of almost 13% from 2020 to 2026.

With current stay-at-home orders due to the COVID-19 health crisis, clinical drug trials shifted to remote monitoring from on-site monitoring. The U.S. Food and Drug Administration ("FDA") now supports remote monitoring for oversight of clinical sites.

In addition, the Mobile Wellbeing platform is equally suited for use in long-term care facilities to care for elderly patients. Big Data features include assisted monitoring that allows for data collection, transmission, evaluation, and notification. Utilizing the latest off-the-shelf wearables, the platform has shown benefits such as improved patient health and also lowered the cost of care through remote monitoring.

Predictmedix anticipates the commercial launch of its remote patient monitoring platform Q1/2021 with some key, large-scale deployments in North America and Asia.

Predictmedix is currently trading at \$0.46 with a market cap of \$46.5M but with billion-dollar partners and a pipeline of projects in Q1/2021, clearly ready for a re-rating.

Predictmedix is starting to commercialize as AI health screening & monitoring takes off

written by InvestorNews | April 15, 2021

Health screening is big business these days. The latest way is using Artificial Intelligence (AI) to mass screen and/or monitor for impairment and various disease states, including COVID-19.

One company is now starting to commercialize their technology, winning contracts and forming distribution partners all around the globe. That company is [Predictmedix Inc.](#) (CSE: PMED | OTCQB: PMEDF).

The global market size for AI in healthcare in 2017 was US\$1.4b and is forecast to rise to reach [US\\$28b](#) by 2025, for **an approximate 20 fold increase in just 8 years**. Healthcare screening and monitoring using AI can play a key role.

The global market for artificial intelligence (AI) in healthcare is forecast to take off



[Source](#)

Predictmedix has developed leading disruptive AI technology in impairment detection and healthcare screenings. Their AI powered products use facial, thermal, video and audio recognition technologies to determine when individuals are suffering from infectious disease, are drug or alcohol impaired, or have a mental illness. The Predictmedix screening devices are backed up by a remote patient monitoring platform.



[Source](#)

Predictmedix's latest achievements to commercialize their screening AI technology

- [October 1, 2020](#) – Partnered with Versus Systems to develop tools for clinical trials, in particular on-site monitoring to ensure human subject protection, data integrity, and quality. The news release [states](#): “This will allow Predictmedix to enter a new industry vertical of clinical trials which is a \$40 billion market opportunity as estimated by Fortune Business Insights.”
- [September 3, 2020](#) – Predictmedix Inc. and Juiceworks Exhibits provide safe entry solutions to facility managers at IFMA World Workplace in Texas.
- [August 17, 2020](#) – Predictmedix Inc. and Juiceworks Exhibits announce COVID-19 technology deployments in North America.
- [August 12, 2020](#) – Deployment of Impairment Screening along with COVID-19 symptom screening technology at Indian Oil Corporation.
- [July 7, 2020](#) – Sales/distributor 1 year contract with Taurus Medical in the United Kingdom. Taurus Medical manufacture and market over 1,500 products for the

diagnosis, treatment and monitoring of respiratory conditions. They are a supplier for the UK National Health Service. Taurus is offering Predictmedix COVID-19 mass screening entry modules to the healthcare, retail, and the entertainment sector in the UK.

- [June 26, 2020](#) – Teamed up with Tech Mahindra who will resell Predictmedix to their global client base. Tech Mahindra is a \$4.9 billion dollar company owned by Mahindra Group. Tech Mahindra is operational across 90 countries, helping 973 global customers including Fortune 500 companies.

Regarding the Indian Oil Corporation contract Predictmedix [state](#):

“The deployment of our COVID-19 screening and impairment technology at IOCL which is a fortune 500 company marks our entry into the Oil & Gas sector which is one of the largest industrial sectors and it further highlights the market need for the suite of technologies developed by Predictmedix.”

Now that’s a very busy past 5 months. The model of using well known brands (Juiceworks Exhibits, Taurus Medical, Tech Mahindra) with large distribution networks should make for a faster and more successful commercialization. Product deployment at large corporations such as Indian Oil Corporation show solid early demand for the Predictmedix product.

Predictmedix operates under a SaaS model. Clients pay a monthly fee based on tiered volume of screenings or by number of device feeds. Both pricing options provide Predictmedix with recurring monthly revenue and multi-year contracts.

Right now as COVID-19 cases approach [40 million](#) (and 1.2 million deaths) it certainly looks like there is a massive potential market for Predictmedix’s COVID-19 Safe Entry Solutions. This

could be the product that rapidly launches Predictmedix into the AI health screening market. You can read more on that [here](#).

Predictmedix current market cap is C\$58m. The Company looks to have plenty of growth opportunities ahead as it strives to capture a share of the forecast [US\\$28b](#) AI healthcare market by 2025.

Further learning

- [Predictmedix's Dr. Rahul Kushwah on using AI to solve real world problems](#)

Predictmedix's Dr. Rahul Kushwah on using AI to solve real world problems

written by InvestorNews | April 15, 2021

Using artificial intelligence to mass screen for COVID-19

"It's about the different verticals that we are addressing with Predictmedix," says Dr. Rahul Kushwah, Co-Founder and COO of [Predictmedix Inc.](#) (CSE: PMED | OTCQB: PMEDF). "We are an artificial intelligence company and we are solving real-world problems."

In an interview with InvestorIntel's Tracy Weslosky, Dr. Kushwah explains three of their vertical markets: "COVID-19 pandemic, we are all in the midst of it and we have a technology which is to mass screen for COVID-19. Similarly, impairment is a

big issue when it comes to workplace and law enforcement and we have a solution for that. And the third vertical is mental illnesses. \$300 billion spent in the US last year and there is so much subjectivity that goes into diagnosis and we are developing a solution to diagnose mental illnesses.”

“We have developed modules which look like metal detectors,” Dr. Kushwah continued. “You walk through these modules and on the other end you have a green or red light. If someone is identified to be positive for COVID-19 symptoms a red light goes off – if not then you get a green light.” He continued, “it is a tool that you can use for mass screening in airports, transit hubs, malls, office building, government buildings, or anywhere you can imagine where you have big flow of people.” Dr. Kushwah also discusses the pitfalls of current telehealth and telemedicine platforms, and Predictmedix’s innovative solutions.

To access the complete interview, [click here](#)

Disclaimer: Predictmedix Inc. is an advertorial member of InvestorIntel Corp.

Predictmedix’s Dr. Kushwah on how AI technology for mass screening of COVID-19 is here

written by InvestorNews | April 15, 2021

“We have developed a technology to screening for COVID-19 and the key is, it is a mass screening technology. The technology works with multispectral imaging and our AI algorithms, which

are patent pending and sit on a cloud, and they communicate directly with the multispectral cameras. These cameras can be installed and as people are passing by, the technology will just screen them for COVID-19.” States Dr. Rahul Kushwah, Co-Founder and COO of [Predictmedix Inc.](#) (CSE: PMED | OTCQB: PMEDF), in an interview with InvestorIntel’s Tracy Weslosky.

Dr. Kushwah went on to say that the technology can be deployed in places where there is movement of large number of people like airports, shopping centers, malls, arenas, transit hubs, etc. He added, “If you want to control the next wave you have to ensure that there is no transmission of infection and the only way you can do that is by containment and to contain you have to identify.”

Dr. Kushwah also provided an update on the appointment of Microsoft Director of Business Development for AI solutions, Kapil Raval, as the Chairman of the Advisory Board. He said that Predictmedix is working very closely with the Indian Institute of Technology to scale up its technologies. Dr. Kushwah also said that Predictmedix has deployed its mass screening technology for COVID-19 with Max Healthcare. He continued, “Max Healthcare is one the largest healthcare group in South Asia...They have 14 hospitals with over 3000 doctors, and we have deployed our technology at their facilities. That is a phenomenal validation to what we have developed.”

To access the complete interview, [click here](#)

Disclaimer: Predictmedix Inc. is an advertorial member of InvestorIntel Corp.

The Perfect Market Storm: Critical Materials, Cleantech and COVID-19

written by Tracy Weslosky | April 15, 2021

There seems to be a misguided notion (with some) that isolation means we have more time to waste. Far from reality, I am certain that many of you, like me are looking at your inbox wondering where or how to wade into the depth of quality deals and opportunities upon us...

Would like to kick your morning coffee off with a special nod to our longstanding friends from [Avalon Advanced Materials Inc.](#) (TSX: AVL | OTCQB: AVLNF) whose \$AVL soared 50% yesterday. We have been supporters of #Avalon since Don Bubar first did an interview with me in 2009 (with Jack Lifton) and introduced me to rare earths. And indeed, there is news flow in the rare earths a-n-d throughout the critical materials sector that is literally ricocheting from source-to-source online...

[How to follow?](#)

Jack Lifton, Clint Adam Smyth and I just launched the [TechnologyMetals.com](#) site to manage the influx of critical materials' news (and experts) we are communicating with regularly. Jack's interview with Dr. David Dreisinger on [Search Minerals Inc.](#) (TSXV: SMY) last week was purely outstanding (in my opinion) as he describes David as "the leading authority on solvent extraction process". This is a hot topic that we touch on in our weekly update that we just started...[click here to access a preview](#)

And associated technologies relating to cleantech? We saw [Exro](#)

[Technologies Inc.](#) (CSE: XRO | OTCQB: EXROF) stock move up 30% yesterday! Interviewing CEO Sue Ozdemir on how Exro makes “electric motors faster, stronger and greener” for InvestorIntel on Wednesday: we will get this up live as fast as we can!

Uranium continues to maintain a much-deserved interest, let me point you in the right direction for a quick update – Matt Bohlsen’s piece from last week titled, [The DoE’s plan to rebuild the uranium sector and ‘pull America’s nuclear industrial base back from the brink of collapse’...](#) reinforces the sustainability themes we are touting on the Technology Metals Show. Arranging interviews as we speak with Mark Chalmers of [Energy Fuels Inc.](#) (NYSE: UUUU | TSX: EFR) and Jeff Klenda of [Ur-Energy Inc.](#) (NYSE: URG | TSX: URE) as they “stand to be the major beneficiaries, especially given they started the whole S232 petition back in January 2018” you should see those live on InvestorIntel next week.

And yes, we are following the biotech and life sciences market. If you subscribe to our AI driven market updates on InvestorChannel.com – you can catch the 20 companies, we are following in the race for vaccinations...[click here](#)

Speaking of AI technology, we would like to ensure that you are aware of the news that was put out by [Predictmedix Inc.](#) (CSE: PMED | OTCQB: PMEDF) yesterday titled – [Predictmedix Files Patent for Mass Screening for Infectious Diseases Such As #COVID19](#)



1 YR stock Chart for Predictmedix Inc. (CSE: PMED) – Source: TD Waterhouse

And speaking on the war against the COVID-19, [StageZero Life Sciences Ltd.](#) (TSX: SZLS) put out the following news on April

20th [StageZero Life Sciences Initiates Testing for COVID-19 In the USA](#)

Remember, click here to subscribe to the [InvestorChannel](#) for daily market updates on the Canadian, US and Hong Kong markets – and to follow InvestorIntel's stock watchlist for Gold, Uranium, Rare Earths and of course, COVID-19...